

Development of Hepatotoxicity Model in Rats and its Application in Evaluation of Hepatoprotective Activity of Cell Wall Contents of Probiotics

Shah G H^{1*}, Patel B G², Shah G B³

¹Department of Pharmacology & Toxicology, Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, CHARUSAT– campus, Changa, Tal- Petlad, Dist. Anand, Pin code -388421. Gujarat, India.

²Charotar University of Science and Technology, CHARUSAT– campus, Changa, Tal- Petlad, Dist.- Anand, Pin code - 388421. Gujarat, India.

³K.B.Institute of Pharmaceutical Education and Research, KBIPER, Sec-23, Gh-6, Gandhinagar.

Available Online:25th July, 2017

ABSTRACT

The objective of present work is Development of Hepatotoxicity model in rats and to evaluate hepatoprotective activity of cell wall contents of probiotics. Animals were divided in four groups. The groups were normal saline group, diseased control group, standard drug treated group and 4th group was CCl₄ +Cell wall contents of probiotics. In diseased control group chronic liver injury was induced by administration of Carbon tetrachloride (CCl₄) via intraperitoneal route (1 ml/kg) for seventy days. For standard drug treated group 1 ml Silymarin suspension (Orally) & CCl₄ was given for seventy days. In fourth group cell wall contents (1 x 10¹² CFU/ml/animal) and CCl₄ was given for seventy days. During disease induction & treatment period blood samples were collected and serum was separated which was used to analyse various parameters like Alanine aminotransferase (ALT), Aspartate aminotransferase, (AST), Alkaline phosphate (ALP), direct bilirubin, total protein and albumin levels to assess liver function. Along with these cholesterol, Glucose and Malondialdehyde were also measured. Liver fibrosis & cirrhosis was quantified by histopathological studies of small portion of the excised liver. Serum AST, ALT, ALP, and direct bilirubin were found to be significantly higher in CCl₄ intoxicated rats. Total protein and albumin was decreased. Malondialdehyde was found to be significantly higher in CCl₄ intoxicated rats which was main end product of Lipid Peroxidation. Whereas in cell wall contents probiotics and silymarin treated group improve the liver functions in CCl₄ toxicated rats. We conclude that protein oxidation may play a role in the pathogenesis of CCl₄ induced liver injury and that the accumulation of oxidised proteins may be an early indication of CCl₄ induced liver damage. Silymarin and cell wall contents of probiotics were effective in liver injury by inhibiting protein oxidation.

Keywords: Liver Fibrosis, Free Radicals, Lipid Peroxidation, Oxidative Stress, Carbon Tetrachloride, liver biomarkers, Cell wall content of probiotics.

INTRODUCTION

Liver is the lymphoid organ which normally regulates innate immune responses through modulation of TLR signal called 'Liver Tolerance'^{1,2}. A breakdown of tolerance may induce in-appropriate immune response leads to Acute and Chronic Liver diseases². Many cell types present in the liver involved in Liver injury¹. Recruitment of immune cells into the liver leads to the activation of local kupffer cells, which can further promote the fibrotic process via secretion of inflammatory and fibrogenic cytokines. Types and duration of liver injury can decide extent of fibrosis and inflammation.

CCl₄ is highly hepato- and nephrotoxicant³ and found to be useful to study hepatotoxic effect in experimental model⁴. Dose and duration of exposure of CCl₄, covers a variety of effects. At low doses, transient effects prevail, such as loss of Ca²⁺ homeostasis⁵, lipid peroxidation⁶,

release of noxious or beneficial cytokines⁷ and apoptotic events followed by regeneration and at the with higher doses develop fatty degeneration, fibrosis, cirrhosis and even cancer⁸. Extreme doses of CCl₄ develop central nervous system depression and respiratory failure and death⁹.

Probiotics are live organisms that, when ingested in adequate amounts, confer a health benefit to the host¹⁰. The most commonly used probiotics are Lactobacilli, Bifidobacterium¹¹. Ex. Of Lactobacillus species are L.acidophilus, L.casei, L.fermentum, L.jhonsonii, L.plantarum, L.rhamnosus & Bifidobacterium species are B.bifidum, B.breves, B.lactis, B.longum¹² It was found that Lactobacillus and Bifidobacterium were able to suppress transcription of IL-1 β , TNF- α , NF- κ B, as well as the translation of IL-1 β and IL-6 in experimental colitis in Rats¹³. L.acidophilus have been reported to prevent cytokine induced intestinal

epithelial permeability that may play significant role in intestinal epithelial cells¹⁴. Probiotic therapies can reduce liver aminotransferases, total-cholesterol, TNF- α and improve insulin resistance in NAFLD¹⁵. Probiotics also decreases intestinal permeability and endotoxemia in patients with liver disease¹⁶. Probiotics improve lipid peroxidation level by maintaining malondialdehyde (MDA) level - as marker of oxidative stress¹⁷. Lipoic acid and dihydrolipoic acid serve as strong antioxidants through several mechanisms, including the scavenging of free radicals, chelation of metal ions, and regeneration of endogenous and exogenous antioxidants, such as ubiquinone, glutathione, and ascorbic acid¹⁸.

Cell wall Content Isolation¹⁹

20 gm bacteria (by weighing colonies) was suspended in 350 ml of hot water (65-68°C). In that 350 ml of 90% Phenol (65-68°C) was added & Stirred for 1hr. at 65-68°C. It was cooled in an ice bath to 2-8°C, or left overnight refrigerator. It was centrifuged at 3000 rpm for 45min. Then, upper water layer was preserved (hot phase). Residual Phenol & inter-phase was treated, if any, with another volume of hot water and proceeded as described. The Phenol layer contain lipids and the insoluble residue of cell wall proteins whereas, Aqueous phase will contain Lipoteichoic acid, Polysaccharides, Teichoic acid and Peptidoglycans. The aqueous layer was used for treatment.

HPTLC method for cell wall contents of probiotics

Probiotics (Test- Mixture of lactobacilli) were taken and cell wall contents were estimated by in house HPTLC method. The CAMAG HPTLC (CAMAG, Muttenz, Switzerland) with Win CATS Software version 1.3.4 along with sample applicator Linomat V were used for HPTLC analysis of the sample. The stock solutions (10 mg/mL) of lipoic acid (LPA) and Lipoteichoic acid (LTA) was prepared by dissolving the freeze dried powders in sterile water for injection. Test compounds were prepared by Phenol-water extraction method as described above in materials and methods section. Two microlitre of different test solutions and reference solutions (LPA) and Lipoteichoic Acid (LTA) were applied on precoated silica gel (10*10) of uniform thickness (0.2mm). The plate was developed in solvent system [n-Propyl alcohol: Ethyl acetate: 25% NH₃: Water (10:5:2.5:2.5) (For Lipoic Acid) and Chloroform: Acetone: Methanol: Glacial acetic acid: water (4.6: 1.7: 1.5: 1.4: 0.8) for Lipoteichoic acid] to a distance of 8 cm. The distance between the tracks was kept 10 mm with bandwidth of 6 mm. The plates were developed in CAMAG flat bottom and Twin trough Chamber (20 × 10 cm). The saturation time was kept 30 min. The temperature was maintained at 25±10°C throughout the study. Initially, the developed plates were visualized using UV visible chamber (CAMAG, Muttenz, Switzerland) to ascertain adequate separation of the components. Finger print profile, and Rf value, were determined densitometrically at 200nm for Lipoic Acid and 540 nm for Lipoteichoic Acid using CAMAG TLC scanner 3.

MATERIALS AND METHODS

Carbon Tetrachloride (CCl₄) & Arachis oil - Loba chemie Pvt Ltd, Mumbai.

Silymarin Suspension – Microlabs Ltd, Bengaluru, Karnataka

SGPT, SGOT, Bilirubin, Total Protein, Albumin, Glucose, Cholesterol, Kits- Autospan (Span Diagnostic Pvt Limited Surat)

Cell Wall Contents of Probiotics

Experimental protocol & procedure

Animals

Healthy Wistar rats of either sex, weighing 200-250 gm was approved by CPCSEA/IAEC committee before carrying out the experiments. The protocol of present study with protocol no RPCP/IAEC/2013-2014/R-32. The animals were housed in polypropylene cage at 25°C; 12 hrs dark-light cycle, with free access to standard pellet diet (normal pellet diet) and water *ad libitum* during the course of experiment. The animals were acclimatized to surrounding for one week prior to experiment.

Experimental design

Rats were randomly divided as follows:

Group I: Received Normal Saline 1 ml/kg per day for 70 days

Group II: Received Carbon Tetrachloride 1 ml/kg for 70 days

Group III: Received Carbon Tetrachloride 1 ml/kg (i.p) & 1 ml Silymarin Suspension (p.o) for 70 days.

Group IV: Received Carbon Tetrachloride 1 ml/kg 1st for 70 days daily and 1 x 10¹² CFU/ml/ of cell wall contents of probiotics for 70 days

Blood Sample Collection

Blood samples were collected by retro-orbital route in EDTA containing and EDTA free vials on day 0, 7, 14, 21, 28, 35, 49, 56, 63 & 70 during development & treatment of the model. After collection of blood samples, the samples were centrifuged under cooling condition at 4000 RPM for 10-15 minutes to separate plasma & serum respectively to measure all biochemical parameters such as AST, ALT, Bilirubin, albumin, total protein, Glucose, Cholesterol, Malondialdehyde except ALP and serum which was used to measure ALP activity.

Histopathological Investigation

Rats were kept on fasting and were sacrificed on day 70. Liver was collected and washed with ice cold saline. The excised liver was fixed in 10 % formalin solution and taken to the Anand Agricultural University (AAU), Department of histopathology, for histopathological study. The extent of CCl₄ induced liver injury was evaluated by assessing the morphological changes in liver sections stained with Haematoxylin & Eosin Stain (H&E Stain) and Masson's trichomes stain to observe liver fibrosis. The therapeutic effect of cell wall contents and probiotics and silymarin was also evaluated by assessing the liver section.

Statistical Analysis

All parameters were expressed as mean value ± S.D. Difference between mean value of tests and controls were evaluated statistically by Student's t-test. P value of < 0.05 was regarded as statistically significant.




Figure 1: TLC Plate showing the spot of isolated cell wall component (Lipoic Acid) & Standard Lipoic acid.




Figure 2: TLC Plate showing the spot of isolated cell wall component (Lipotechoic Acid) & Standard Lipotechoic acid.




Figure 3: HPTLC for Lipoic Acid.




Figure 4: HPTLC for Lipotechoic Acid.

Table 1: Change in various serum parameters in rats exposed to CCl₄ daily and normal saline.

Group	ALP	ALT	AST	Bilirubin	T.P
Normal Control	P-0.0258, 303.8 ± 30.95	P-0.0015 480.± 51.04	P-0.018, 518.3 ± 57.71	P-0.025, 0.4795 ±0.07	P-0.0106, 4.794 ±0.20
CCl ₄ treated	P-0.0258 199.5 ± 31.05	P-0.0015 243.9±41.7	P-0.018, 262.0 ± 44.89	P-0.025, 0.1881 ±0.04	P-0.0106, 5.640 ± 0.23
Group	Albumin	Globulin	MDA	Glucose	Cholesterol
Normal control	P-0.0342, 2.427 ± 0.23	P-0.0122 2.538± 0.09	P-0.0058, 1.791 ± 0.11	P-0.0001, 196.2 ±10.8	P-0.0001, 214.3 ± 12.41
CCl ₄ treated	P-0.0342 3.355 ± 0.34	P-0.0122 2.285± 0.20	P-0.0058, 0.3350 ±0.04	P-0.0001, 116.0 ± 12.9	P-0.0001, 111.1 ± 15.74

Data was expressed as mean±SEM (n=6) Significant difference was indicated by p<0.5 compared with normal control group.

P value between Normal control and CCl₄ treated group is <0.5, which indicates they are statistically significant.

ALP-Alkaline phosphate, ALT- Alanine Transaminase, AST-Aspartate transaminase, T.P –Total protein, MDA- Malondialdehyde

RESULTS AND DISCUSSION

Hepatotoxicity by CCl₄ depends on dose and its duration of exposure. Chronic dose of CCl₄ (1 ml /kg, i.p) serve as hepatotoxicant. Upon chronic exposure of CCl₄, rise was observed in serum enzyme levels, which is shown in Table. Along with liver enzymes, Albumin, Total protein & MDA is also affected.

Table 1 shows that when CCl₄ was given daily, there was rise in ALP, AST, malondialdehyde (MDA), Glucose, Cholesterol & Globulin. However different scenario was seen in normal controls, standard drug treated group and the group which was given cell wall contents of probiotics. Here P value between Normal control and CCl₄ treated group (table 1), CCl₄ treated group and standard drug treated group (table 2), CCl₄ treated group

and cell wall contents of probiotic treated group (table 3) is <0.5, which indicates they are statistically significant. Whereas P value between standard group treated group and cell wall contents of probiotics treated group is not<0.5, which indicates no significant difference in between this group.

Histopathological Findings

The controlled rats were showed normal liver architecture. They showed normal hepatocytes, portal triads vasculature, and bile duct. Whereas rats which were given CCl₄ up to 70 days shows extensive liver damage. Silymarin treated rats and rats treated with cell wall contents of probiotics showed normal liver architecture.

DISCUSSION

Table 2: Change in various serum parameters in rats exposed to CCl₄ treated and standard drug treated group.

Group	ALP	ALT	AST	Bilirubin	T.P
CCl ₄ treated	P-0.0083, 238.1 ± 19.52	P-0.0003 499.7±58.7	P-0.013, 550.5 ± 63.62	P-0.0001, 0.3950 ±0.05	P-0.0371, 4.827 ±0.24
Standard Drug (Silymarin) Treated	P-0.0083 138.3 ± 27.91	P-0.0003 169.3±48.5	P-0.013, 290.8 ± 71.34	P-0.0001, 0.0943 ±0.02	P-0.0371, 5.647 ±0.27
Group	Albumin	Globulin	MDA	Glucose	Cholesterol
CCl ₄ treated	P-0.0124, 2.372 ± 0.32	P-0.0250 2.455± 0.01	P-0.0058, 1.791 ± 0.10	P-0.014, 188.8 ± 11.2	P-0.0001, 213.2 ± 13.43
Standard Drug (Silymarin) Treated	P-0.0124 3.658 ± 0.35	P-0.0250 1.989± 0.17	P-0.0058, 0.3350 ±0.05	P-0.014, 118.8 ± 15.2	P-0.0001, 113.8 ± 16.85

Data was expressed as mean±SEM (n=6) Significant difference was indicated by p<0.5.

P value between CCl₄ treated group and Standard drug treated group was <0.5, which indicates they are statistically significant.

Table 3: Change in various serum parameters in rats exposed to CCl₄ treated and cell wall contents of probiotics treated group

Group	ALP	ALT	AST	Bilirubin	T.P
CCl ₄ treated	P-0.0258, 303.8 ± 30.95	P-0.0015 480.± 51.04	P-0.018, 518.3 ± 57.71	P-0.025, 0.4795 ±0.07	P-0.0106, 4.794 ±0.20
Cell Wall contents of probiotics treated	P-0.0258 199.5 ± 31.05	P-0.0015 243.9±41.7	P-0.018, 262.0 ± 44.89	P-0.025, 0.1881 ±0.04	P-0.0106, 5.640 ± 0.23
Group	Albumin	Globulin	MDA	Glucose	Cholesterol
CCl ₄ treated	P-0.0342, 2.427 ± 0.23	P-0.0122 2.538± 0.09	P-0.0058, 1.791 ± 0.11	P-0.0001, 196.2 ±10.8	P-0.0001, 214.3 ± 12.41
Cell Wall contents of probiotics treated	P-0.0342 3.355 ± 0.34	P-0.0122 2.285± 0.20	P-0.0058, 0.3350 ±0.04	P-0.0001, 116.0 ± 12.9	P-0.0001, 111.1 ± 15.74

Data was expressed as mean±SEM (n=6) Significant difference was indicated by p<0.5

P value between CCl₄ treated group and cell wall contents of probiotics treated group was <0.5, which indicates they are statistically significant.

The haematopoietic system is very sensitive to toxic compounds and serves as an important index of the physiological and pathological status for both animals and humans¹⁹. Hematototoxicology is the study of adverse effects of drugs, non-therapeutic chemicals and other agents in our environment on blood and blood-forming tissues²⁰. This subspecialty draws on the discipline of hematology and the principles of toxicology. The vital functions that blood cells perform, together with the susceptibility of this highly proliferative tissue to intoxication, makes the haematopoietic system unique as a target organ. Accordingly, it ranks with liver and kidney as one of the most important considerations in the risk assessment of individual patient populations exposed to potential toxicants in the environment, workplace, and medicine cabinet.

Serum aminotransferase enzymes

Biochemical parameters are an important marker to evaluate the organs and cellular functions. Among the evaluated parameters, such as AST, ALT, and ALP, total bilirubin, unconjugated bilirubin and conjugated bilirubin, total protein, albumin, globulin, and A/G ratio are considered as liver function markers²¹. The analysis of

these parameters is important because several reports of liver toxicity are related to the use of phytotherapeutic products²².

The most specific test for hepatocellular damage is the ALT level. The AST may also be elevated but is not as specific as the ALT. The ALT is the gold test in hepatocellular damage. AST and ALT are enzymes that are present in all the cells, however, they are found in highest concentration in the hepatocytes: ALT in the cytoplasm and AST in the cytoplasm as well as the mitochondria²³. Cholestatic injury is best diagnosed by an elevated ALP level. Bile acids stimulate ALP production, but duct obstruction or damage prevents bile acid secretion into the duodenum. Therefore, the ALP level in serum rises dramatically. Because ALP can be derived from other body tissues (e.g. bone, intestine), a concurrent elevation of GGT helps to support a cholestatic mechanism.

In the present study serum AST, ALT, ALP, Bilirubin activities were greatly increased (p < 0.05) in rats exposed to CCl₄ as compare to normal control. The increased serum levels of hepatic markers have been attributed to the liver injury, because these enzymes are




Figure 4a. Normal Histology of liver




Figure 4b: Proliferation of fibrous were Evident in hepatic lobule resulting into pseudolobulation (Day 70)




Figure 4c: Did not reveal any specific changes (CCl₄ + Silymarin)




Figure 4d: Did not reveal any specific lesion (CCl₄ + cell wall contents of probiotics 1 x 10¹² CFU/ml/animal)

place in cytoplasmic area of the cell and are released into circulation in case of cellular damage.

L.acidophilus have been reported to prevent cytokine induced intestinal epithelial permeability that may play significant role in Intestinal epithelial cells²⁴. It has been reported that probiotic therapies can reduce liver aminotransferases, total-cholesterol, TNF- α and improve insulin resistance in NAFLD²⁵. *Lactobacillus GG* (LGG) could prevent endotoxemia which was due to its ability to improve barrier function²⁶. It was studied that lipoic acid and Lipotechoic acid can serve as antioxidant through scavenging of free radicals, chelation of metal ions and regeneration of endogenous and exogenous antioxidant²⁷.

CONCLUSION

From the results and discussion it was concluded that Carbon Tetrachloride has potential to cause chronic liver injury (Fibrosis & Cirrhosis). The proposed animal model of chronic liver injury might be suitable for screening of drugs used to treat liver injury and associated disorders. Here Silymarin as a standard drug which shows hepatoprotective effect in developed model.

In current study, cell wall contents of (lactobacilli bacteria) probiotics were highly effective in treating chronic liver disease. The cell wall components of probiotics (Lipoic acid & Lipotechoic acid) are highly

effective in treatment of liver disease by inhibiting lipid peroxidation and normalizing the liver enzymes level.

CONFLICT OF INTEREST

The authors acknowledge Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology (CHARUSAT) for financial support.

ACKNOWLEDGEMENTS

The author is thankful to Dr. B.G.Patel for his scientific advice. The author wants to thank Ms. Gopi Shah for her writing assistance.

REFERENCES

1. Seki E, Brenner DA. Toll like receptors and adaptor molecules in liver disease:update. *Hepatology* 2008;48:322-335.
2. Chen Y, Sun R. Toll like receptor in liver injury and regeneration. *International Immunopharmacology* 2011;1:1-9.
3. Ogeturk, M., I. Kus, N. Colakoglu, I. Zararsiz, N. Ilhan and M. Sarsilmaz. Caffeic acid phenethyl ester protects kidneys against carbon tetrachloride in rats. *Journal of Ethnopharmacology* 2005;97: 273-280.
4. Muriel P., Fernandez-Martinez E., Perez-Alvarez V., Lara-Ochoa F., Ponce S., Garcia J., Shibayama M. and

- Tsutsumi V. Thalidomide ameliorates CCl₄-cirrhosis in the rat. *Eur J Hepatol Gastroenterol* 2003;15: 951–957.
5. Muriel P., Mourelle, M. Prevention by silymarin of membrane alterations in acute CCl₄ liver damage. *J Appl Toxicol* 1990;10: 275-279.
 6. Muriel P. Peroxidation of lipids and liver damage, in S. I. Baskin and H. Salem (eds), *Oxidants and Free Radicals*, Taylor & Francis, Washington, DC, USA, 1997;237–257.
 7. Kyung-Hyun K., Hyun-Chul K., Mee-Yul H., Hoon-Kyu O., Tae Sung L., Young Chae C., Ho-Jung S., Nam-Hee W. and Kwan-Kyu P. The antifibrotic effect of TGF-β1 siRNAs in murine model of liver cirrhosis. *Biochem Biophys Res Commun* 2006;343: 1072–1078.
 8. Weber, L.W., Boll, M., Stampfl, A. Hepatotoxicity and mechanism of action of haloalkanes: Carbon tetrachloride as a toxicological model. *Crit Rev Toxicol* 2003;33:105–136.
 9. Berger, L. M., Bhatt, H., Combes, B. and Estabrock, R. W. CCl₄-induced toxicity in isolated hepatocytes: the importance of direct solvent injury. *Hepatology* 1986;6: 36–45.
 10. M. Van de Bovenkamp, G.M.M. Groothuis, D.K.F. Meijer, P. Olinga. Liver fibrosis in vitro: Cell culture models and precision-cut liver slices. *Toxicology in Vitro* 2007; 21:545–557.
 11. Reid, G. The importance of guidelines in the development and application of probiotics. *Curr. Pharm. Des.* 2005;11:11–16.
 12. McNaught CE, Macfie J. Probiotics in clinical practice: a critical review of the evidence. *Nutrition research* 2001;21:343-353.
 13. Borchers AT, Selmi C, Meyers FJ, Keen CL, Gershwin ME. Probiotics and immunity. *J Gastroenterol* 2009;44:26-46.
 14. Karimi O, Pena AS, van Bodegraven AA. Probiotics (VSL3) in arthralgia in patients with ulcerative colitis and Crohn's disease: a pilot study. *Drugs Today (Barc)* 2005; 41: 453–459.
 15. Yan-Yan Ma, Lin Li, Chao-Hui Yu, Zhe Shen, Li-Hua Chen, You-Ming Li. Effects of probiotics on nonalcoholic fatty liver disease: A meta-analysis. 2013;19(40):10-19.
 16. Malaguarnera M, Gargante MP, Malaguarnera G, Salmeri M, Mastrojeni S, Rampello L, Pennisi G, Li Volti G, Galvano F. Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy. *Eur J Gastroenterol Hepatol* 2010; 22: 199-206.
 17. Kozlov, A.V., Gille, L., Staniek, K., Nohl, H.. Dihydrolipoic acid maintains ubiquinone in the antioxidant active form by two-electron reduction of ubiquinone and one-electron reduction of ubiquinol. *Arch. Biochem. Biophys* 1999; 363:148–154.
 18. Roberson BS and Cromatte WJ. Influence of the physical state of endotoxic preparations on dermal toxicity. *Journal of Bacteriology* 1962;84:882-887.
 19. Adeneye, A.A., Ajagbonna, O.P., Adeleke, T.I., Bello, S.O. Preliminary toxicity and phytochemical studies of the stem bark aqueous extract of *Musanga cecropioides* in rats. *J Ethnopharmacology*. 2006;105: 374-379.
 20. Bloom, J.C. Introduction to hematotoxicology, in Sipes I.G, McQueen C.A, Gandolfi A.J (eds.): *Comprehensive Toxicology*. Oxford, UK: Pergamon Press. 1997;1–10.
 21. Palmeiro, N.M.S., Almeida, C.E., Ghedini, P.C., Goulart, L.S., Pereira, M.C.F., and Huber, S. Oral subchronic toxicity of aqueous crude extract of *Plantago australis* leaves. *J Ethnopharm.* 2003;88:15–18.
 22. Corns, C.M. Herbal remedies and clinical biochemistry. *Ann Clin Biochem* 2003; 40:489–507.
 23. Al-Habori M, Al-Aghbari A, Al-Mamary M, Baker M. Toxicological evaluation of *Catha edulis* leaves: a long term feeding experiment in animals. *J Ethnopharmacol.* 2002;83: 209–217.
 24. Karimi O, Pena AS, van Bodegraven AA. Probiotics (VSL3) in arthralgia in patients with ulcerative colitis and Crohn's disease: a pilot study. *Drugs Today (Barc)* 2005; 41: 453–459.
 25. Yan-Yan Ma, Lin Li, Chao-Hui Yu, Zhe Shen, Li-Hua Chen, You-Ming Li. Effects of probiotics on nonalcoholic fatty liver disease: A meta-analysis. 2013;19(40):10-19.
 26. Bode C, Bode JC. Activation of the innate immune system and alcoholic liver disease: effects of ethanol per se or enhanced intestinal translocation of bacterial toxins induced by ethanol? *Alcohol Clin Exp Res* 2005;29:166S–171S.
 27. Sunji S, Rieko A, Hidemi R, and Haruhiko T. Lipoteichoic Acid Acts as an Antagonist and an Agonist of Lipopolysaccharide on Human Gingival Fibroblasts and Monocytes in a CD14-Dependent Manner. *Infection and Immunity* 1999;67(4):1623–1632.